Production of Poliovirus Vaccines: Past, Present, and Future

Duchêne, Michel; Peetermans, J; D'Hondt, E.; Harford, N; Fabry, L.; Stephenne, J

doi:10.1089/vim.1990.3.243

Cited by 27 publications

(8 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The different culture conditions used per cell line represented envisioned production conditions for each cell line for a direct comparison of production platforms. Vero cell cultivation mimicked as closely as possible cIPV production as described in literature [28][29][30][31]. When certain parameters were unknown, conditions were optimized (shaking speed, cell seeding density, micro-carrier type and time post seeding prior to inoculation) to obtain the highest cell density for infection.…”

Section: Sabin Strain Infection Results In Higher Infectious Titer Anmentioning

confidence: 99%

Production of high titer attenuated poliovirus strains on the serum-free PER.C6® cell culture platform for the generation of safe and affordable next generation IPV

Sanders

Oakes

Hoek

et al. 2015

Vaccine

View full text Add to dashboard Cite

Sabin and rationally-attenuated polioviruses can be grown to high infectious titers and D-antigen yields. Sabin strain infection shows increased productivity on the PER.C6(®) cell platform as compared to the conventional Vero cell platform. Novel cell platforms with the potential for higher yields could contribute to increased affordability of a next generation of IPV vaccines needed for achieving and maintaining poliovirus eradication.

show abstract

Section: Sabin Strain Infection Results In Higher Infectious Titer Anmentioning

confidence: 99%

Production of high titer attenuated poliovirus strains on the serum-free PER.C6® cell culture platform for the generation of safe and affordable next generation IPV

Sanders

Oakes

Hoek

et al. 2015

Vaccine

View full text Add to dashboard Cite

show abstract

“…In OPV manufacturing, the virus cultivation temperature for Sabin PV is lower (at a maximum of 35°C [24]) than the temperature used for wild-type PV in conventional IPV manufacturing (36-37°C) [18,35]. This lower temperature is required to ensure the temperature sensitivity of the Sabin PV and minimize revertants to ensure a safe OPV.…”

Section: Resultsmentioning

confidence: 99%

“…In principle, OPV manufacturers could, by acquiring correct downstream processing (DSP) equipment, produce sIPV. However, larger quantities of virus harvest (100-800 fold of current production quantities) are needed and upstream processing (USP) should be scaled-up [18]. …”

Section: Introductionmentioning

confidence: 99%

Next Generation Inactivated Polio Vaccine Manufacturing to Support Post Polio-Eradication Biosafety Goals

et al. 2013

View full text Add to dashboard Cite

Worldwide efforts to eradicate polio caused a tipping point in polio vaccination strategies. A switch from the oral polio vaccine, which can cause circulating and virulent vaccine derived polioviruses, to inactivated polio vaccines (IPV) is scheduled. Moreover, a manufacturing process, using attenuated virus strains instead of wild-type polioviruses, is demanded to enhance worldwide production of IPV, especially in low- and middle income countries. Therefore, development of an IPV from attenuated (Sabin) poliovirus strains (sIPV) was pursued. Starting from the current IPV production process based on wild type Salk strains, adaptations, such as lower virus cultivation temperature, were implemented. sIPV was produced at industrial scale followed by formulation of both plain and aluminium adjuvanted sIPV. The final products met the quality criteria, were immunogenic in rats, showed no toxicity in rabbits and could be released for testing in the clinic. Concluding, sIPV was developed to manufacturing scale. The technology can be transferred worldwide to support post polio-eradication biosafety goals.

show abstract

“…OPV/Sabin strain content also varies considerably depending on the medium (Table V). Cell culture harvests in OPV production facilities are on the order of 10 8 CCID 50 /ml under standard production conditions of 34°C, ( 50 ) but often exist as concentrates of 10 10 to 10 11 CCID 50 /ml. OPV formulations are in a 10‐1‐3 or 10‐1‐6 ratio, that is, 10 × 10 5 – 1 × 10 5 – 6 × 10 5 CCID 50 /dose for types 1, 2, and 3, respectively.…”

Section: Infectious and Potential Infectious Materialsmentioning

confidence: 99%

“…OPV formulations are in a 10‐1‐3 or 10‐1‐6 ratio, that is, 10 × 10 5 – 1 × 10 5 – 6 × 10 5 CCID 50 /dose for types 1, 2, and 3, respectively. ( 50,205 ) In the research and diagnostic laboratory, cell culture titers may be a few fold less for Sabin than for WPV, ( 124 ) but are very similar on the average. Also similar to WPV, pharyngeal secretions range from >10 2 to 10 4.5 CCID 50 /swab ( 85 ) and peak titers in stools range between 10 5.1 and 10 6.2 CCID 50 /gm.…”

Section: Infectious and Potential Infectious Materialsmentioning

confidence: 99%

Containment of Polioviruses After Eradication and OPV Cessation: Characterizing Risks to Improve Management

Dowdle

Avoort²,

Gourville³

et al. 2006

Risk Analysis

View full text Add to dashboard Cite

The goal of the World Health Organization is to stop routine use of oral poliovirus vaccine shortly after interruption of wild poliovirus transmission. A key component of this goal is to minimize the risk of reintroduction by destruction of polioviruses except in an absolute minimum number of facilities that serve essential functions and implement effective containment. Effective containment begins with a complete facility risk assessment. This article focuses on characterizing the risks of exposure to polioviruses from the essential vaccine production, quality control, and international reference and research facilities that remain. We consider the potential exposure pathways that might lead to a poliovirus reintroduction, including para-occupational exposures and releases to the environment, and review the literature to provide available estimates and a qualitative assessment of containment risks. Minimizing the risk of poliovirus transmission from a poliovirus facility to increasingly susceptible communities is a crucial and ongoing effort requiring understanding and actively managing the potential exposure pathways.

show abstract

Production of Poliovirus Vaccines: Past, Present, and Future

Cited by 27 publications

References 44 publications

Production of high titer attenuated poliovirus strains on the serum-free PER.C6® cell culture platform for the generation of safe and affordable next generation IPV

Production of high titer attenuated poliovirus strains on the serum-free PER.C6® cell culture platform for the generation of safe and affordable next generation IPV

Next Generation Inactivated Polio Vaccine Manufacturing to Support Post Polio-Eradication Biosafety Goals

Containment of Polioviruses After Eradication and OPV Cessation: Characterizing Risks to Improve Management

Contact Info

Product

Resources

About